Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael O'Kelly

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Pharmaceutical Statistics|January 29, 2011
Making available information from studies sponsored by the pharmaceutical industry: some current practicesMichael O'Kelly, Steven A Julious, Stephen Pyke, et al.
Therapeutic Innovation & Regulatory Science|February 20, 2020
Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into PracticeBohdana Ratitch, James Bell, Craig Mallinckrodt, et al.
Therapeutic Innovation & Regulatory Science|February 20, 2020
Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) GuidelinesBohdana Ratitch, Niti Goel, Craig Mallinckrodt, et al.
Pharmaceutical Statistics|March 22, 2016
Estimands: discussion points from the PSI estimands and sensitivity expert groupAlan Phillips, Juan Abellan-Andres, Andersen Soren, et al.
Trials|August 2, 2020
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trialTom Wilkinson, Rupert Dixon, Clive Page, et al.
Cancer Cell|February 5, 2010
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, et al.
Nature Genetics|October 6, 2009
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomasAdam J Bass, Hideo Watanabe, Craig H Mermel, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Pharmaceutical Statistics|January 29, 2011
Making available information from studies sponsored by the pharmaceutical industry: some current practicesMichael O'Kelly, Steven A Julious, Stephen Pyke, et al.
Therapeutic Innovation & Regulatory Science|February 20, 2020
Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into PracticeBohdana Ratitch, James Bell, Craig Mallinckrodt, et al.
Therapeutic Innovation & Regulatory Science|February 20, 2020
Defining Efficacy Estimands in Clinical Trials: Examples Illustrating ICH E9(R1) GuidelinesBohdana Ratitch, Niti Goel, Craig Mallinckrodt, et al.
Pharmaceutical Statistics|March 22, 2016
Estimands: discussion points from the PSI estimands and sensitivity expert groupAlan Phillips, Juan Abellan-Andres, Andersen Soren, et al.
Trials|August 2, 2020
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trialTom Wilkinson, Rupert Dixon, Clive Page, et al.
Cancer Cell|February 5, 2010
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, et al.
Nature Genetics|October 6, 2009
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomasAdam J Bass, Hideo Watanabe, Craig H Mermel, et al.
Pageof 2